Intercept Pharmaceuticals (ICPT) Management Meeting Thoughts, RBC Capital Remains on the Sidelines
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $33.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
